Evidence map›Paper›PMID 40820976›Full record

ArticleJournal of the American Heart Association2025

Improving "No-Reflow" After Complete Reperfusion: The Role of Intravenous Thrombolysis in Vertebrobasilar Artery Occlusion Patients Undergoing Endovascular Treatment.

Zhanglin Li, Yingjie Xu, Pan Zhang, Miaomiao Hu, Ruyue Wang, Zhixin Huang, Zuowei Duan, Xinfeng Liu, Wen Sun

Abstract readMulticenter Study
In one paragraph

Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhanglin LiDepartment of Neurology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui China.ORCID 0009-0001-6813-8589
Yingjie XuDepartment of Neurology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui China.ORCID 0000-0002-4181-7450
Pan ZhangDepartment of Neurology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui China.ORCID 0000-0001-6320-6987
Miaomiao HuDepartment of Neurology Bengbu Medical College Bengbu Anhui China.ORCID 0009-0006-1821-0534
Ruyue WangDepartment of Neurology Bengbu Medical College Bengbu Anhui China.ORCID 0009-0008-4184-744X
Zhixin HuangDepartment of Neurology Guangdong Second Provincial General Hospital Guangzhou Guangdong China.
Zuowei DuanDepartment of Neurology Second Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu China.
Xinfeng LiuDepartment of Neurology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui China.ORCID 0000-0002-8182-9632
Wen SunDepartment of Neurology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui China.ORCID 0000-0002-7268-2085

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious studies have found that the use of intravenous thrombolysis (IVT) before endovascular treatment (EVT) could mitigate the "no-reflow" phenomenon in large-vessel occlusion of the anterior circulation. However, the effect of preoperative IVT on reducing the "no-reflow" phenomenon in vertebrobasilar artery occlusion (VBAO) is still uncertain. This study aimed to compare the outcomes of IVT before EVT versus EVT alone in patients with VBAO with complete reperfusion (mTICI [Modified Thrombolysis in Cerebral Infarction] 3).

methodsWe performed a retrospective analysis of patients with acute VBAO at 65 stroke centers in China. Patients with complete reperfusion after EVT were included. These patients were divided into 2 groups on the basis of whether IVT was used before EVT, and propensity score matching was applied to balance the groups. The primary outcome was favorable functional outcome, defined as a modified Rankin Scale score of 0 to 3 at 90 days. Secondary outcomes were functional independence (modified Rankin Scale score of 0-2 at 90 days) and modified Rankin Scale shift at 90 days. Safety end points included symptomatic intracranial hemorrhage and death at 90 days.

resultsOf the 2422 patients with VBAO who received EVT, 1452 patients achieved complete reperfusion. Among these, 273 patients received IVT before EVT. After propensity score matching, 268 patients treated with IVT before EVT were compared with 519 patients without IVT. In the matched cohort, the group that received IVT before EVT showed a higher rate of favorable functional outcome (modified Rankin Scale score, 0-3) (adjusted odds ratio, 1.40 [95% CI, 1.03-1.91];

conclusionsOur study indicates that IVT before EVT could improve favorable functional outcomes and reduce death in patients with VBAO who achieve complete reperfusion.

Indexed as

Endovascular ProceduresFibrinolytic AgentsThrombolytic TherapyVertebrobasilar InsufficiencyAgedChinaFemaleHumansMaleMiddle AgedPropensity ScoreReperfusionRetrospective StudiesTime FactorsTreatment OutcomeFibrinolytic Agentsendovascular treatmentintravenous thrombolysisno‐reflow phenomenonvertebrobasilar artery occlusion

Identifiers

PMID40820976
PMCPMC12748070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.